Dendritic cells: On the move from bench to bedside.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 11433329.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
As dendritic cells increasingly become the adjuvant of choice in new approaches to cancer immunotherapy, a degree of protocol standardization is required to aid future large-scale clinical trials.
Medical subject headings
- Cancer Vaccines
- Dendritic Cells